Monte Rosa Therapeutics (GLUE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.43
- Estimate
- -$0.37
- Surprise
- -17.6%
- Revenue (period 2026-06-30)
- $9.0M
- Score today
- 4.4/10
Revenue source: xbrl.
How the report landed
Monte Rosa Therapeutics (GLUE) reported a wider loss than forecast — adjusted EPS of -$0.43 against the -$0.37 estimate (a 17.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates GLUE Sell at 4.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -17.6% surprise compares with a -23.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (1.5 < 4.0)
- Momentum score 3.3/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.12
- Price target
- $23.38
- Stop
- $9.41
- Upside to target
- +131.0%
- Reward-to-risk
- 10.4:1
Risk check: RSI 29 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
GLUE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $863.4M
- P/E (fwd)
- -5.2
- 52-week range
- $8.94–$25.77
- Off 52-week high
- 60.7%
- RSI (14)
- 29
- Volume vs avg
- 1.04×
- Score today
- 4.4/10